查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1882969

脑膜炎双球菌疫苗市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2024-2032 年）

Meningococcal Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 161 Pages | 商品交期: 请询问到货日

价格

脑膜炎双球菌疫苗市场成长驱动因子

受疫苗可预防的脑膜炎球菌疾病病例数量不断增加以及全球疫苗接种工作不断扩大的推动，全球脑膜炎球菌疫苗市场持续显着增长。根据 2024 年的报告，2024 年脑膜炎双球菌疫苗市场规模达到 35.4 亿美元。预计到 2025 年，该市场规模将成长至 38.1 亿美元，到 2032 年将达到 73.4 亿美元，2025 年至 2032 年的复合年增长率 (CAGR) 为 9.8%。北美地区在 2024 年以 57.34% 的市占率引领全球市场，这反映了该地区较高的疫苗接种率和已获批准疫苗的大规模应用。

脑膜炎双球菌感染（包括脑膜炎、败血症和肺炎）是由脑膜炎奈瑟菌引起的。该菌有12种血清型，其中6种（A、B、C、W、X和Y）是流行的主要原因。细菌性脑膜炎仍然是一种危及生命的疾病，如果不及时治疗，往往会导致严重的神经损伤甚至死亡。脑膜炎双球菌感染的日益流行，加上人们对该疾病认识的提高以及疫苗研发方面的国际合作，持续推动着疫苗市场的显着成长。例如，2024年4月，印度血清研究所与牛津大学合作开发了一种基于嵌合蛋白的B群脑膜炎双球菌疫苗，扩大了未来疫苗研发的潜力。

市场动态

推动因素

细菌性脑膜炎双球菌感染的增加显着推动了疫苗的需求。根据世界卫生组织的数据，六分之一的细菌性脑膜炎患者会死亡，五分之一的患者会遭受长期併发症，例如脑损伤或截肢。 2023年，美国报告了438例脑膜炎球菌疾病病例，这是过去十年来的最高发生率，凸显了疫苗接种计画的紧迫性。这种疾病的上升趋势正在推动对脑膜炎双球菌疫苗（包括常规疫苗和紧急疫苗）的需求激增。

限制因子

结合疫苗的高成本是市场面临的主要阻碍因素。生产流程复杂、多组分配方以及冷链储存要求都推高了价格。根据美国疾病管制与预防中心（CDC）发布的疫苗价格表（2025年6月），Penbrayer疫苗每瓶售价230.75美元，Menquadfi疫苗10剂装售价171.97美元。这可能会延缓低收入地区（缺乏医疗保险）的疫苗普及。

机会

全球疫苗接种计画蕴藏着巨大的成长机会。世界卫生组织（世卫组织）的 "2030年终结脑膜炎" 路线图强调，应扩大免疫规划，并使用价格合理的疫苗，包括Men5CV疫苗。 2025年4月，世卫组织发布了首个关于脑膜炎诊断、治疗和长期照护的全球指南，显着加强了全球应对疫情的准备。

挑战

冷链物流仍然是一项重大挑战，尤其是在资源匮乏的地区。根据英国卫生安全署2023年的报告，可避免的疫苗浪费造成的损失高达330万美元，而不可避免的冷链中断造成的损失则高达370万美元。这些损失正日益加剧公共卫生预算的压力。

市场区隔亮点

2024年，重组疫苗、结合疫苗和次单位疫苗占市场主导地位。这得归功于结合疫苗的广泛应用以及新产品的推出，例如葛兰素史克（GSK）的单剂量Menveo疫苗于2024年11月获批。此外，由于多个国家广泛推行学校疫苗接种建议，MenACWY疫苗在疫苗类型中占领先地位。

2024年，儿科疫苗的需求量最高，这主要得益于一些疫苗适应症的扩展，例如赛诺菲（Sanofi）的Menquadfi疫苗获批用于6週至23个月龄的儿童（于2025年5月获准）。

由于大规模的国家免疫规划，政府机构在2024年成为主要的疫苗通路。例如，在 Gavi 的支持下，尼日利亚于 2024 年 4 月成为首个引入 Men5CV 疫苗的国家。

区域展望

北美仍将是最大的区域市场，2024 年市场规模将达到 20.3 亿美元，这主要得益于脑膜炎球菌疾病 (IMD) 病例的增加以及强大的公共卫生基础设施。 2024年6月，多伦多公共卫生局报告了13例侵袭性脑膜炎球菌疾病（IMD）病例，这是自2002年以来的最高数字。

预计亚太地区将在2024年占第二大占有率，并在2032年之前保持最快的成长速度，这主要得益于疫苗的引入，例如印度血清研究所的MenFive疫苗，该疫苗于2023年7月获得世卫组织预认证。欧洲持续受益于较高的常规免疫接种覆盖率，2022-2023年英格兰儿童的B群脑膜炎双球菌疫苗接种覆盖率达91%。

拉丁美洲和中东/非洲地区仍然是成长型市场，2021年至2023年间，发病率从每10万人0.05例上升至0.18例，尤其是在脑膜炎带地区。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场推动因素
  • 市场阻碍因素
  • 市场机遇
  • 市场趋势

第四章：主要见解

  • 主要国家和地区的监管情况
  • 主要国家和地区的疫苗接种覆盖率
  • 主要国家和地区的政府脑膜炎疫苗接种计划
  • 脑膜炎双球菌疫苗的技术进步
  • 主要产业趋势（併购、合作、新产品发表）等等）

第五章：全球脑膜炎双球菌疫苗市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测 - 依技术分类
    • 重组/结合/次单位疫苗
    • 灭活​​疫苗
    • 其他
  • 市场分析、洞察与预测 - 依类型分类
    • MenACWY疫苗
    • MenB疫苗
    • MenABCWY疫苗
    • 其他
  • 市场分析、洞察与预测 - 依年龄组分类
    • 儿童
    • 成人
  • 市场分析、洞察与预测 - 依销售管道分类
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美脑膜炎双球菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲脑膜炎双球菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 德国
    • 美国王国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区脑膜炎双球菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲脑膜炎双球菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区美国

第十章：中东和非洲脑膜炎双球菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2024）
  • 公司简介
    • 葛兰素史克 (GSK plc)
    • 赛诺菲 (Sanofi)
    • 默克公司 (Merck & Co., Inc.)
    • 印度血清研究所 (Serum Institute of India Pvt.)有限公司
    • 诺华公司
    • 华生生技有限公司
    • 华兰生物疫苗股份有限公司
    • 生物农场
    • 亚洲生物网。
Product Code: FBI113758

Growth Factors of meningococcal vaccines Market

The global meningococcal vaccines market continues to advance significantly, driven by rising cases of vaccine-preventable meningococcal diseases and increasing global immunization efforts. According to the 2024 report, the meningococcal vaccines market size reached USD 3.54 billion in 2024. The market is projected to increase to USD 3.81 billion in 2025 and rise further to USD 7.34 billion by 2032, expanding at a CAGR of 9.8% between 2025 and 2032. In 2024, North America dominated the global market with a 57.34% share, indicating strong vaccination coverage and large-scale adoption of approved vaccines.

Meningococcal diseases-including meningitis, sepsis, and pneumonia-are caused by Neisseria meningitidis. Although 12 serogroups exist, six (A, B, C, W, X, and Y) are responsible for major epidemics. Bacterial meningitis remains life-threatening, often causing severe neurological damage or death if not treated promptly. The rising burden of meningococcal infections, coupled with increasing awareness and global collaborations for vaccine development, continues to drive substantial market growth. For example, in April 2024, the Serum Institute of India partnered with the University of Oxford to develop a chimeric protein-based Men-B vaccine, expanding future vaccine possibilities.

Market Dynamics

Drivers

The increasing number of bacterial meningococcal infections is significantly boosting vaccine demand. WHO reports indicate that 1 in 6 bacterial meningitis patients die, and 1 in 5 suffer long-term complications such as brain damage or amputations. In 2023, the U.S. reported 438 cases of meningococcal disease, the highest incidence in a decade, highlighting the urgent need for immunization programs. Such rising disease patterns support fast-growing demand for both routine and emergency meningococcal vaccinations.

Restraints

A key market restraint is the high cost of conjugate vaccines. Manufacturing complexity, multi-component formulations, and cold-chain storage requirements contribute to elevated pricing. According to the CDC Vaccine Price List (June 2025), Penbraya costs USD 230.75 per vial, while MenQuadfi costs USD 171.97 for a 10-pack dose-prices that may slow adoption in low-income regions without insurance coverage.

Opportunities

Global vaccination initiatives present strong growth opportunities. WHO's "Defeating Meningitis by 2030" roadmap emphasizes expanded immunization programs using affordable vaccines, including Men5CV. In April 2025, WHO released the first global guidelines for meningitis diagnosis, treatment, and long-term care, significantly strengthening global preparedness.

Challenges

Cold-chain logistics remain a major challenge, especially in low-resource settings. As per the 2023 U.K. Health Security Agency report, vaccine wastage due to avoidable reasons cost USD 3.3 million, while unavoidable cold-chain failures cost USD 3.7 million. Such losses increase pressure on public health budgets.

Market Segmentation Highlights

Recombinant/conjugate/subunit vaccines dominated in 2024, supported by widespread availability of conjugate vaccines and new product approvals such as GSK's single-vial Menveo in November 2024. The MenACWY segment led by type due to broad, school-based immunization recommendations across multiple countries.

Pediatric vaccines generated the highest demand in 2024, strengthened by expansions such as Sanofi's MenQuadfi pediatric indication (May 2025) for infants aged 6 weeks to 23 months.

Government suppliers represented the leading distribution channel in 2024 because of large-scale national immunization programs. For example, Nigeria became the first country to introduce Men5CV in April 2024, supported by Gavi.

Regional Outlook

North America remained the dominant region with a 2024 market size of USD 2.03 billion, driven by rising IMD cases and strong public health infrastructure. In June 2024, Toronto Public Health reported 13 IMD cases, the highest since 2002.

Asia Pacific held the second-largest share in 2024 and is projected to grow fastest through 2032, supported by WHO-prequalified vaccines such as Serum Institute's MenFive in July 2023. Europe continues to benefit from high routine immunization coverage, including 91% MenB vaccination-rate among children in England in 2022-23.

Latin America and Middle East & Africa remain growing markets, especially in the meningitis belt, where incidence rose from 0.05 to 0.18 per 100,000 between 2021 and 2023.

Conclusion

With global market value rising from USD 3.54 billion in 2024 to USD 7.34 billion by 2032, the meningococcal vaccines market is set for substantial long-term expansion. Strong R&D efforts, supportive government initiatives, and increased disease awareness will continue to drive growth through 2032.

Segmentation By Technology

  • Recombinant/Conjugate/Subunit
  • Inactivated
  • Others

By Type

  • MenACWY Vaccines
  • MenB Vaccines
  • MenABCWY Vaccines
  • Others

By Age Group

  • Pediatric
  • Adults

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Geography

  • North America (By Technology, Type, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Vaccination Coverage- By Key Countries/ Regions
  • 4.3. Government Immunization Programs for Meningitis, By Key Countries/ Regions
  • 4.4. Technological Advancements in Meningococcal Vaccines Market
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Technology
    • 5.1.1. Recombinant/Conjugate/Subunit
    • 5.1.2. Inactivated
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. MenACWY Vaccines
    • 5.2.2. MenB Vaccines
    • 5.2.3. MenABCWY Vaccines
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Technology
    • 6.1.1. Recombinant/Conjugate/Subunit
    • 6.1.2. Inactivated
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. MenACWY Vaccines
    • 6.2.2. MenB Vaccines
    • 6.2.3. MenABCWY Vaccines
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Technology
    • 7.1.1. Recombinant/Conjugate/Subunit
    • 7.1.2. Inactivated
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. MenACWY Vaccines
    • 7.2.2. MenB Vaccines
    • 7.2.3. MenABCWY Vaccines
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Technology
    • 8.1.1. Recombinant/Conjugate/Subunit
    • 8.1.2. Inactivated
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. MenACWY Vaccines
    • 8.2.2. MenB Vaccines
    • 8.2.3. MenABCWY Vaccines
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Technology
    • 9.1.1. Recombinant/Conjugate/Subunit
    • 9.1.2. Inactivated
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. MenACWY Vaccines
    • 9.2.2. MenB Vaccines
    • 9.2.3. MenABCWY Vaccines
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Meningococcal Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Technology
    • 10.1.1. Recombinant/Conjugate/Subunit
    • 10.1.2. Inactivated
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. MenACWY Vaccines
    • 10.2.2. MenB Vaccines
    • 10.2.3. MenABCWY Vaccines
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adults
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Serum Institute of India Pvt. Ltd.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Novartis AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Walvax Biotechnology Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Hualan Biological Vaccine Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Bio Farma
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. BioNet-Asia.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2019-2032
  • Table 2: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 3: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2019-2032
  • Table 4: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 5: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Region, 2019-2032
  • Table 6: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2019-2032
  • Table 7: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 8: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2019-2032
  • Table 9: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 10: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 11: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2019-2032
  • Table 12: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 13: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2019-2032
  • Table 14: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 15: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2019-2032
  • Table 17: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 18: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2019-2032
  • Table 19: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 20: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2019-2032
  • Table 22: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 23: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2019-2032
  • Table 24: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 25: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 26: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2019-2032
  • Table 27: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 28: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2019-2032
  • Table 29: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 30: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Meningococcal Vaccines Market Revenue Breakdown (USD billion, %) By Region, 2024 & 2032
  • Figure 2: Global Meningococcal Vaccines Market Value Share (%), By Technology, 2024 & 2032
  • Figure 3: Global Meningococcal Vaccines Market Value Share (%), By Type, 2024 & 2032
  • Figure 4: Global Meningococcal Vaccines Market Value Share (%), By Age Group, 2024 & 2032
  • Figure 5: Global Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2024 & 2032
  • Figure 6: Global Meningococcal Vaccines Market Value Share (%), By Region, 2024 & 2032
  • Figure 7: North America Meningococcal Vaccines Market Value (USD billion), By Technology, 2024 & 2032
  • Figure 8: North America Meningococcal Vaccines Market Value Share (%), By Technology, 2024
  • Figure 9: North America Meningococcal Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 10: North America Meningococcal Vaccines Market Value Share (%), By Type, 2024
  • Figure 11: North America Meningococcal Vaccines Market Value (USD billion), By Age Group, 2024 & 2032
  • Figure 12: North America Meningococcal Vaccines Market Value Share (%), By Age Group, 2024
  • Figure 13: North America Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 14: North America Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 15: North America Meningococcal Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Meningococcal Vaccines Market Value Share (%), By Country, 2024
  • Figure 17: Europe Meningococcal Vaccines Market Value (USD billion), By Technology, 2024 & 2032
  • Figure 18: Europe Meningococcal Vaccines Market Value Share (%), By Technology, 2024
  • Figure 19: Europe Meningococcal Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 20: Europe Meningococcal Vaccines Market Value Share (%), By Type, 2024
  • Figure 21: Europe Meningococcal Vaccines Market Value (USD billion), By Age Group, 2024 & 2032
  • Figure 22: Europe Meningococcal Vaccines Market Value Share (%), By Age Group, 2024
  • Figure 23: Europe Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 24: Europe Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 25: Europe Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Technology, 2024 & 2032
  • Figure 28: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Technology, 2024
  • Figure 29: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 30: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Type, 2024
  • Figure 31: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Age Group, 2024 & 2032
  • Figure 32: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Age Group, 2024
  • Figure 33: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 35: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Meningococcal Vaccines Market Value (USD billion), By Technology, 2024 & 2032
  • Figure 38: Latin America Meningococcal Vaccines Market Value Share (%), By Technology, 2024
  • Figure 39: Latin America Meningococcal Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 40: Latin America Meningococcal Vaccines Market Value Share (%), By Type, 2024
  • Figure 41: Latin America Meningococcal Vaccines Market Value (USD billion), By Age Group, 2024 & 2032
  • Figure 42: Latin America Meningococcal Vaccines Market Value Share (%), By Age Group, 2024
  • Figure 43: Latin America Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 45: Latin America Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Technology, 2024 & 2032
  • Figure 48: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Technology, 2024
  • Figure 49: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 50: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Type, 2024
  • Figure 51: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Age Group, 2024 & 2032
  • Figure 52: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Age Group, 2024
  • Figure 53: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 55: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 57: Global Meningococcal Vaccines Market Share (%), By Company, 2024